The chemotherapy-induced oral mucositis market is estimated to secure a valuation of US$ 1.2 Billion in 2023 and is estimated to rise to US$ 2.0 Billion by 2033. The market is anticipated at a CAGR of 5.3% during the forecast period. The factors accelerating the demand for chemotherapy-induced oral mucositis are as follows-
With the increasing prevalence of cancer patients globally, and the growing number of chemotherapy performed the market for chemotherapy-induced oral mucositis is also growing. The side effect of radiation and cytotoxic chemotherapy agents cause oral mucositis, and the demand for treatment of oral microsites is growing, which is expected to drive the growth of the chemotherapy-induced oral mucositis market during the forecast period.
Other factors driving the growth of the chemotherapy-induced oral mucositis market include increased research & development activities for the development of new drugs for oral mucositis and technological advances in biopharmaceuticals.
North America is expected to account for the highest share of the chemotherapy-induced oral mucositis market owing to the increasing healthcare spending and increased R&D activities, presence of skilled professional in the region drive the market growth. The increased rate of patients receiving chemotherapy boosts the market growth.
Europe is projected to be the dominant regional market for chemotherapy-induced oral mucositis throughout the forecast period. The market in the region is driven by the increasing prevalence of cancer cases and growing government support, and increased research activities to develop advanced medical care.
Asia Pacific is expected to be the fastest-growing region in the chemotherapy-induced oral mucositis market. Technological advances in healthcare and increased research & development activities in emerging economies are driving market growth in the Asia Pacific.
Izun Pharmaceuticals, Soleva Pharma, Aurora Bioscience, INNOVATION Pharma, Camurus AB, Monopar Therapeutics, Prothex, Access Pharmaceuticals Inc, Swedish Orphan Biovitrum AB, NeoMedLight are some of the leading players operating in chemotherapy-induced oral mucositis market.
The market players operating in the chemotherapy-induced oral mucositis market are focusing on expanding their product offerings and geographic presence to remain competitive in the market. Also, the leading players in the chemotherapy-induced oral mucositis market players are heavily investing in research & development activities to increase their product portfolio.
For instance, in January 2023- BT BeaMedical Technology owned by Innovation Pharmaceuticals, announced a strategic agreement with Shina System Ltd, in order to build on the unique capabilities of Shina and accelerate its development.
The chemotherapy-induced oral mucositis market is expected to grow in the coming years owing to the prevalence of cancer, advancement in technologies, and growing demand for oral mucositis. The start-ups in the chemotherapy-induced oral mucositis market are using new technologies and innovation and coming up with new technically advanced chemotherapy-induced oral mucositis –products Some of the startups operating in the chemotherapy-induced oral mucositis market are given below-
| Data Point | Key statistics |
|---|---|
| Expected Market Value in 2023 | US$ 1.2 Billion |
| Projected Market Value in 2033 | US$ 2.0 Billion |
| Growth Rate (2023 to 2033) | CAGR of 5.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to the latest research by Future Market Insights, chemotherapy-induced oral mucositis market is set to experience positive growth during the year 2023 to 2033. The global oral mucositis market is witnessing demand every year as cases of oral mucositis become apparent each year.
This demand fluctuates from year to year based on a variety of conditions. This market covers the prescription and sales of oral mucositis drugs worldwide. Oral mucositis is swelling of the tissues of the oral cavity. This medical condition occurs as a common side effect of radiation or chemotherapy.
Oral mucositis is a common health problem caused by cancer treatment and other factors, so this market faces demand in many parts of the world. Therefore, the customer base of oral mucositis in the global market is diversified. Increase in usage of chemotherapeutic agents due to the increasing incidence of cancers is the major growth driver of chemotherapy-induced oral mucositis treatment market.
There are many growing drivers of the oral mucositis market that frequently affect the market. One of the major driver in the oral mucositis market is the increased detection of cancer. This is also the case for the discovery of cases of head and neck cancer. In recent years, the number of patients with cancer has increased.
This also creates a window for oral mucositis and industrial demand window for oral mucositis. Another important factor in the oral mucositis market is the increased elderly population. People get older and more susceptible to cancer because of their current lifestyle.
These factors also affect the oral mucositis market as the increase in the number of patients receiving chemotherapy each year. Increasing prevalence of cancer propel the growth of Chemotherapy-Induced Oral Mucositis Market.
Principal Consultant
Chemotherapy treatment causes oral mucositis in 35% of patients. The incidence of oral mucositis was particularly high in patients with tumours in the oropharynx or nasopharynx, patients receiving concomitant chemotherapy, patients with total doses greater than 5000 cGy, and patients. Treated with an altered split radiation schedule.
Enzychem Lifesciences, has a mid-term experimental oral compound called EC18 for OM induced by chemoradiation therapy.
About half a million people in the United States suffer from oral mucositis each year, and oral mucositis represents a new market in which unmet health care needs are largely intrinsically a long-standing problem. It is estimated that 40% of cancer patients who receive standard chemotherapy will develop oral mucositis.
The Centres for Disease Control and Prevention estimates that approximately 650,000 cancer patients in the United States receive chemotherapy in an outpatient environment each year.Generally speaking, there is an agreement that there are about 500,000 oral mucositis cases each year in the United States today. Adding financial burden makes the market opportunity to solve oral mucositis clearer.
Innovation Pharma evaluated Buriracizine in a fast-track designation in a gargle, Phase II clinical trial to reduce oral mucositis in patients with head and neck cancer (HNC) who received chemo radiation therapy. NCI scientists developed palifermin, a very successful treatment for preventing and treating oral mucositis.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Mucositis is a common complication of chemotherapy, radiation therapy, and targeted formulations. This often affects chemotherapy compliance because it induces schedule delays, treatment interruptions or discontinuations. Also, the economic impact associated with the management of mucositis is local, and some estimates of additional hospital costs due to these clinical conditions have recently been reported.
The ability to determine risk factors for mucositis, detect early onset, accurately assess the degree of toxicity, and plan multidisciplinary management ensures quality of life for all patients and of this drug it is an important factor in avoiding unnecessary capacity reduction or discontinuation in the treatment.
BMG Pharma in 2018 got the European regulatory approval for its GelX product to be used for the prevention of oral mucositis. episil® (Camurus AB) oral liquid – a treatment for intraoral pain caused by oral mucositis
Some of the key players operating in the Chemotherapy-Induced Oral Mucositis Market are
MuGard®, Soleva Pharma Oral mucoadhesive is indicated for the management of oral mucositis/stomatitis and all kinds of oral wounds (inflammation and damage) including inflammation/ulcer pain and traumatic ulcers. As a result of intraoral surgery or improper fit of dentures or braces.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Healthcare
March 2022
REP-GB-1364
July 2022
211 pages
Healthcare
January 2022
REP-GB-8116
July 2022
207 pages
Explore Healthcare Insights
View Reports
Chemotherapy-Induced Oral Mucositis Market
